Advances in cancer immunotherapy 2019 – latest trends
Ludwig-Maximilians-Universität München · LMU Klinikum · +6 more institutions
Abstract
Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. The two main drivers behind this success are checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells. This review summarizes seminal findings from clinical and translational studies recently presented or published at important meetings or in top-tier journals, respectively. For checkpoint blockade, current studies focus on combinational approaches, perioperative use, new tumor entities, response prediction, toxicity management and use in special patient populations. Regarding cellular immunotherapy, recent studies confirmed…
Citation impact
- FWCI
- 36.48
- Percentile
- 100%
- References
- 116
Authors
15- SKStephan KrügerCorresponding
Ludwig-Maximilians-Universität München, LMU Klinikum
- MIMatthias Ilmer
Ludwig-Maximilians-Universität München, German Cancer Research Center, Heidelberg University, LMU Klinikum
- SKSebastian Kobold
Center for Integrated Protein Science Munich, Ludwig-Maximilians-Universität München
- BLBruno L. Cadilha
Ludwig-Maximilians-Universität München, Center for Integrated Protein Science Munich
- SEStefan Endres
Ludwig-Maximilians-Universität München, Center for Integrated Protein Science Munich
Topics & keywords
- Medicine
- Immunotherapy
- Clinical trial
- Chimeric antigen receptor
- Cancer immunotherapy
- Cancer
- Oncology
- Lymphoma
- Good health and well-being